/ABVX
ABVX Stock - Abivax S.A.
Healthcare|BiotechnologyNASDAQ
$114.94+1.17%
+$1.33 (+1.17%) • Dec 19
88
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.93
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+26.0%upside
Target: $144.82
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ABVX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$113.79 – $116.09
TARGET (TP)$144.88
STOP LOSS$105.74
RISK/REWARD1:3.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.11
52W High$138.49
52W Low$4.77
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.79M | $4.62M | $4.58M | $37,000 | $63,000 |
| Gross Profit | $10.79M | $4.57M | $4.47M | $-119,000 | $-33,769,000 |
| Gross Margin | 100.0% | 99.0% | 97.6% | -321.6% | -53601.6% |
| Operating Income | $-172,984,000 | $-127,376,000 | $-64,836,000 | $-41,400,000 | $-38,008,000 |
| Net Income | $-176,242,000 | $-147,740,000 | $-60,740,000 | $-42,452,000 | $-37,551,000 |
| Net Margin | -1633.1% | -3197.1% | -1325.3% | -114735.1% | -59604.8% |
| EPS | $-2.80 | $-3.43 | $-3.18 | $-2.75 | $-2.62 |
Company Overview
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
78%
Hold / Neutral
2
22%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish2 Neutral/Bearish
Price Targets
$59
Average Target
↓ 48.4% Downside
Now
$12
Low
$59
Average
$176
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| November 6th 2025 | Wolfe Research | Initiation | Outperform | $176 |
| October 13th 2025 | Barclays | Initiation | Overweight | $142 |
| July 23rd 2025 | Morgan Stanley | Upgrade | Overweight | $71 |
| March 20th 2025 | Morgan Stanley | Initiation | Equal Weight | $12 |
| December 4th 2024 | JMP Securities | Initiation | Mkt Outperform | $33 |
| July 29th 2024 | Laidlaw | Initiation | Buy | $48 |
| May 20th 2024 | BTIG Research | Initiation | Buy | $43 |
| April 29th 2024 | Piper Sandler | Initiation | Overweight | $42 |
| April 29th 2024 | Guggenheim | Initiation | Buy | $50 |
| November 14th 2023 | Morgan Stanley | Initiation | Equal Weight | $15 |
| November 14th 2023 | Leerink Partners | Initiation | Outperform | $20 |
Earnings History & Surprises
ABVXBeat Rate
40%
Last 5 quarters
Avg Surprise
-38.3%
EPS vs Estimate
Beats / Misses
2/3
Last 12 quarters
Latest EPS
$-0.86
Q3 2025
EPS Surprise History
Q4 21
No data
Q2 22
No data
Q4 22
-0.8%
$-1.95vs$-1.93
Q2 23
No data
Q2 24
-112.7%
$-1.94vs$-0.91
Q4 24
+45.5%
$-0.70vs$-1.28
Q1 25
-128.0%
$-1.55vs$-0.68
Q3 25
+4.4%
$-0.86vs$-0.90
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-2.24 | — | — | — |
Q3 2025 | Sep 8, 2025 | $-0.90 | $-0.86 | +4.4% | ✓ BEAT |
Q1 2025 | Mar 24, 2025 | $-0.68 | $-1.55 | -128.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-1.28 | $-0.70 | +45.5% | ✓ BEAT |
Q2 2024 | Apr 2, 2024 | $-0.91 | $-1.94 | -112.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-1.58 | — | — |
Q4 2022 | Dec 31, 2022 | $-1.93 | $-1.95 | -0.8% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | — | $-1.84 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.68 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.34 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.90 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.42 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1.53 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.57 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.98 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.84 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.66 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.65 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.64 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.95 | — | — |
Latest News
Abivax SA To Be Added To The Nasdaq Biotechnology Index, Effective Prior To Market Open On December 22, 2025
📈 PositiveBenzinga•Dec 18, 2025, 09:07 PM
Abivax SA To Present 22 Scientific Abstracts Detailing Advancements In The Understanding Of Obefazimod For The Treatment Of Inflammatory Bowel Disease At The European Crohn's And Colitis Organization's 21st Annual Congress Taking Place February 18-21, 2026 In Stockholm, Sweden
📈 PositiveBenzinga•Dec 17, 2025, 09:08 PM
Citizens Maintains Market Outperform on Abivax, Raises Price Target to $131
📈 PositiveBenzinga•Dec 16, 2025, 11:18 AM
Abivax Presents Q3 2025 Financial Results; Cash And Cash Equivalents Of €589.7 Million, As Of September 30, 2025, With A Cash Runway Into Q4 2027
📈 PositiveBenzinga•Dec 15, 2025, 09:11 PM
Eli Lilly acquisition rumors reportedly fuel Abivax rally
📈 PositiveSeeking Alpha•Dec 10, 2025, 12:49 PM•Also:
Truist Securities Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $140
📈 PositiveBenzinga•Nov 24, 2025, 05:47 PM
Watching Abivax SA; Shares Trading Higher, Traders Circulate Unconfirmed Rumor From M&A Blog
📈 PositiveBenzinga•Nov 20, 2025, 03:48 PM
Wolfe Research Initiates Coverage On Abivax with Outperform Rating, Announces Price Target of $176
📈 PositiveBenzinga•Nov 6, 2025, 01:22 PM
Abivax Data From Phase 3 ABTECT 8-Week Induction Studies Of Obefazimod Improves Quality Of Life For Participants Suffering From Active Ulcerative Colitis
📈 PositiveBenzinga•Nov 3, 2025, 09:16 PM
Barclays Initiates Coverage On Abivax with Overweight Rating, Announces Price Target of $142
📈 PositiveBenzinga•Oct 13, 2025, 11:58 AM•Also:
Guggenheim Maintains Buy on Abivax, Raises Price Target to $150
📈 PositiveBenzinga•Oct 10, 2025, 12:36 PM
BTIG Maintains Buy on Abivax, Raises Price Target to $120
📈 PositiveBenzinga•Oct 7, 2025, 09:56 AM
Abivax shares are trading higher after the company announced results from the ABTECT-1 and ABTECT-2 trials demonstrated that obefazimod met its FDA primary endpoint.
📈 PositiveBenzinga•Oct 6, 2025, 01:09 PM
Abivax Drug Obefazimod Shows Results In Phase 3 Ulcerative Colitis Trials
📈 PositiveBenzinga•Oct 6, 2025, 08:07 AM
Reported Sunday, Abivax Announces Late-Breaking Phase 3 Data Showing Obefazimod Achieved 16.4% Placebo-Adjusted Remission Rate At Week 8 In Ulcerative Colitis
📈 PositiveBenzinga•Oct 6, 2025, 06:32 AM
Abivax SA Will Present Second Late-breaking Abstract On Its Lead Drug Candidate Obefazimod For Treating Moderately To Severely Active Ulcerative Colitis At United European Gastroenterology Congress
📈 PositiveBenzinga•Sep 29, 2025, 08:10 PM
JMP Securities Maintains Market Outperform on Abivax, Raises Price Target to $114
📈 PositiveBenzinga•Sep 25, 2025, 01:06 PM
AbivaxTo Present Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology
📈 PositiveBenzinga•Sep 23, 2025, 08:09 PM
Morgan Stanley Maintains Overweight on Abivax, Raises Price Target to $101
📈 PositiveBenzinga•Sep 12, 2025, 03:37 PM
BTIG Reiterates Buy on Abivax, Maintains $112 Price Target
📈 PositiveBenzinga•Sep 9, 2025, 11:15 AM
Frequently Asked Questions about ABVX
What is ABVX's current stock price?
Abivax S.A. (ABVX) is currently trading at $114.94 per share. The stock has moved +1.17% today.
What is the analyst price target for ABVX?
The average analyst price target for ABVX is $144.88, based on 1 analyst.
What sector is Abivax S.A. in?
Abivax S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ABVX's market cap?
Abivax S.A. has a market capitalization of $7.54 billion, making it a mid-cap company.
Does ABVX pay dividends?
No, Abivax S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CORT
Corcept Therapeutics Incorporated
$83.76
Mkt Cap: $8.8B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to ABVX for comparison